SEWOONMEDICAL CO,. LTD.
KOSDAQ
₩2,415.00
+0.00%
Delayed · cached 15 min
Fair value analysis
100700
SEWOONMEDICAL CO,. LTD.
₩2,415.00
Close used for this calculation
₩4,256.36Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
74/100
Quality radar
Consensus fair value
₩4,256.36
Below FV▲ +76.2% against the close used
Model range ₩948.60 – ₩5,691.60
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩948.60Fair value₩4,256.36Bull₩5,691.60
FairClose
52-week traded range
52W low ₩2,220.0052W high ₩2,470.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
SEWOONMEDICAL CO,. LTD. closed at ₩2,415.00, 43.3% below the consensus fair value of ₩4,256.36 drawn from 10 valuation models.
Financial DNA score 74/100 — Strong. P/E of 8.7x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩5,292.57
+119.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=3.4%, r=10%, tg=3%, n=10yr
Graham Number
₩4,756.80
+97.0%
√(22.5 × EPS × BVPS)
EPS=279, BVPS=3604.48
Graham Formula
₩5,691.60
+135.7%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=3.4%, FD=3.3%
P/E Fair Value
₩5,580.00
+131.1%
EPS × 20x (sector P/E)
EPS=279, Sector P/E=20x
Peter Lynch (PEG)
₩948.60
-60.7%
EPS × Growth% (PEG = 1 is fair)
EPS=279, g=3.4%
EV/EBITDA
₩3,400.29
+40.8%
(EBITDA × 11.7x − Net Debt) ÷ Shares
EBITDA=12.7B
Dividend Discount (DDM)
₩1,059.38
-56.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=67.62, r=10%, g=3.4%
Book Value (P/B)
₩2,446.68
+1.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=3604.48, ROE=7.9%, g=3.4%, r=10%
Reverse DCF
₩2,415.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -4.3% | Historical: 3.4%
Margin of Safety
₩3,997.68
+65.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=5330.24, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.